

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Applicant:**

Michal AYALON-SOFFER et al

Serial No.: 10/764,833

Filed: January 27, 2004

**For:** NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE  
POLYPEPTIDES AND METHODS USING SAME

**Examiner:**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



Group Art Unit: 1631

Attorney  
Docket: 27256

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This application is a CIP of 10/426,002 filed 04/30/03 and is a CIP of 10/242,799 filed 09/13/2002. Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin O. Myrick

Martin Moynihan  
Registration No. 40,338

Dated: October 3, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
3a	EP 0770349		02-2-1997	Akasaka		
4	PCT WO 98/55510		12-10-1998	Hillman et al.		
5	PCT WO 02/12341		02-14-2002	Cheever et al.		
6	PCT WO 2004/092338		10-28-2004	Macina et al.		
7	PCT WO 2005/033133		04-14-2005	Shemesh et al.		
8	PCT WO 2004/096980		11-11-2004	Ayalon-Soffer et al.		
9	PCT WO 2004/096979		11-11-2004	Mintz et al.		

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
Sheet		Of		Attorney Docket Number
				27256
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	10	Tullo et al. "Reorganization and Merging of the EMBL and GenBank Keyword Indexes in A Tree Structure for More Efficient Retrieval of Nucleic Acid Sequences", Protein Sequences and Data Analysis, 3: 327-334, 1990.		
	11	Shoshan et al. "Designing Oligo Libraries Taking Alternative Splicing Into Account", Proc. SPIE., 4266: 86-95.		
	12	Michel et al. "Identification of A Novel IL-6 Isoform Binding to Endogenous IL-6 Receptor", Annual Journal Respir. Cell Molecular Biology, 27: 48-56, 2002.		
	13	Croft "Costimulatory Members of the TNFR Family: Keys to Effective T-Cell Immunity?" Nature Reviews, 3: 609-, 2003.		
	14	Aigner et al. "Expression of A Truncated 100 kDa HER2 Splice Variants Acts as An Endogenous Inhibitor of Tumour Cell Proliferation", Oncogene, 20(17): 2101-2111, 2001.		
	15	Gebhardt et al. "Differential Expression of Alternatively Spliced C-Erb-B-2 mRNA in Primary Tumors, Lymph Node Metastases, and Bone Marrow Micrometastases From Breast Cancer Patients", Biochemical and Biophysical Research Communications, 247(2): 319-323, 1998.		
	16	Kwong et al. "A Novel Splice Variant of HER2 With Increased Transformation Activity", Molecular Carcinogenesis, 23(2): 62-68, 1988.		
	17	Azios et al. "Expression of Herstatin, An Autoinhibitor of HER-2/Neu, Inhibits Transactivation of HER-3 by HER-2 and Blocks EGF Activation of the EGF Receptor", Oncogene, 20(37): 5199-5232, 2001.		
	18	Strausberg et al. "Homo Sapiens Ubiquitin-Conjugating Enzyme E2C, mRNA (cDNA Clone IMAGE: 5574059), Partial Cds", Database EMBL 'Online! Database Accession No. BC032677, 2202. See: "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences", Proc. Natl. Acad. Sci. USA, 99(26): 16899-16903, 2002.		
	19	??? "AGENCOURT_6578352 NIH_MGC_41 Homo Sapiens cDNA Clone IMAGE: 5467535 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BM556795, 2002.		
	20	??? "AGENCOURT_7952308 NIH_MGC_72 Homo Sapiens cDNA Clone IMAGE: 6149711 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BU171488, 2002.		
	21	Townsley et al. "Dominant-Negative Cyclin-Selective Ubiquitin Carrier Protein E2-C/UBCH10 Blocks Cells in Metaphase", Proc. Natl. Acad. Sci. USA, 94(6): 2362-2367, 1997.		
	22	Schlegel et al. "Human Cervical Cancer Cell Marker Protein SEQ ID NO: 228", Database Geneseq 'Online!, Database Accession No. ABR92159, 2003. & WO 02/101075, 2002.		
	23	Okamoto et al. "UbcH10 Is the Cancer-Related E2 Ubiquitin-Conjugating Enzyme", Cancer Research, 63(14): 4167-4173, 2003.		
	24	??? "OTTHUMP00000031654 (Fragment)", Database EMBL, Database Accession No. Q9BQP0, 2001. Abstract.		
	25	Reeck et al. "'Homology' in Proteins and Nucleic Acids: A Terminology Muddle and A Way Out of It", Cell, 50: 667, 1987.		
	26	??? "AGENCOURT_785234 NIH_MGC_67 Homo Sapiens cDNA Clone IMAGE: 6140098 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BU169315, 2002.		

	27	Krawczak et al. "The Mutational Spectrum of Single Base-Pair Substitutions in mRNA Splice Junctions of Human Genes: Causes and Consequences", Human Genetics, 90: 41-54, 1992.	
	28	Boguski et al. "ESTablishing A Human Transcript Map", Nature Genetics, 10: 369-371, 1995.	
	29	Schena et al. "Quantitative Monitoring of Gene Expression Patterns With A Complementary DNA Microarray", Science, 270: 467-470, 1995.	
	30	Velculescu et al. "Serial Analysis of Gene Expression", Science, 270: 484-487, 1995.	
	31	Hillier et al. "Generation and Analysis of 280,000 Human Expressed Sequence Tags", Genome Research, P. 807-828.	
	32	Dwight et al. "Saccharomyces Genome Database (SGD) Provides Secondary Gene Annotation Using the Gene Ontology (GO)", Nucleic Acids Research, 30(1): 69-72, 2002.	
	33	Matloubian et al. "A Transmembrane CXC Chemokine Is A Ligand for HIV-Coreceptor Bonzo", Nature Immunology, 1(4): 298-304, 2000.	
	34	David et al. "Unusual Alternative Splicing Within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-Specific Proteins", The Journal of Biological Chemistry, 2277(20): 18084-18090; 2002.	
	35	Camargo et al. "The Contribution of 700,000 ORF Sequence Tags to the Definition of the Human Transcriptome", PNAS, 98(21): 12103-12108, 2001.	
	36	Caron et al. "The Human Transcriptome Map: Clustering of Highly Expressed Genes in Chromosomal Domains", Science, 291: 1289-1292, 2001.	
	37	Audic et al. "The Significance of Digital Gene Expression Profiles", Genome Research, 7: 986-995, 1997.	
	38	Huminiecki et al. "In Silico Cloning of Novel Endothelial-Specific Genes", Genome Research, 10: 1796-1806, 2000.	
	39	Kawamoto et al. "BodyMap: A Collection of 3' ESTs for Analysis of Human Gene Expression Information", Genome Research, 10: 1817-1827, 2000.	
	40	Liu et al. "A Mechanism for Exon Skipping Caused by Nonsense or Missense Mutations in BRCA1 and Other Genes", Nature Genetics, 27: 55-58, 2001.	
	41	Brett et al. "EST Comparison Indicates 38% of Human mRNAs Contain Possible Alternative Splice Forms", FEBS Letters, 474: 83-86, 2000.	
	42	Croft et al. "ISIS, the Intron Information System, Reveals the High Frequency of Alternative Splicing in the Human Genome", Nature Genetics, 24: 340-341, 2000.	
	43	Burset et al. "Analysis of Canonical and Non-Canonical Splice Sites in Mammalian Genomes", Nucleic Acids Research, 28(21): 4364-4375, 2000.	
	44	Boguski "Biosequence Exegesis", Science, 286: 453-455, 1999.	
	45	Doherty et al. "The HER-2/Neu Receptor Tyrosine Kinase Gene Encodes A Secreted Autoinhibitor", Medical Sciences, 96(19): 10869-10874, 1999.	
	46	Nahta et al. "Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention", The Oncologist, 8(1): 5-17, 2003.	
	47	Younes et al. "Labelled Oligonucleotides as Radiopharmaceuticals: Pitfalls, Problems and Perspectives", Current Pharmaceutical Design, 8: 1451-1466, 2002.	
	48	Sazani et al. "Modulation of Alternative Splicing by Antisense Oligonucleotides", Progress in Molecular and Subcellular Biology, 31: 217-239, 2003.	

Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.